As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients Caveat: The guidance is optional. Will states opt in?

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

The Senate has released its version of a 2027 continuing resolution that would fund the U.S. government through Dec. 11.

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

The Centers for Medicare & Medicaid Services is planning a 33.4% cut to the reimbursement payments hospitals receive for all drugs acquired through the 340B program, according to a draft guidance published on July 7.

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

The Centers for Medicare & Medicaid Services has proposed a sweeping new Advance Care Planning quality measure (MUC2025-020) that would track end-of-life care discussions for patients 18 and older.

July 10, 2026

Vol.52 No.27

By Claire Marie Porter

Cancer Policy

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

The U.S Supreme Court has declined to hear a slew of legal challenges filed by pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novo Nordisk, Novartis, and Boehringer Ingelheim.

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

Cancer Policy

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.

April 24, 2026

Vol.52 No.16

As Medicaid work requirements loom, CMS guidance offers automatic exemptions for some cancer patients

Caveat: The guidance is optional. Will states opt in?

YOU MAY BE INTERESTED IN

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

Supreme Court rejects pharma challenges against CMS drug price negotiating powers

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

Renew today!

Subscriber content

Never miss an issue!

Login